Stockscreener 앱 받기
0.3639
20.46%
0.0618
시간 외 거래:
.37
0.0061
+1.68%
Ernexa Therapeutics Inc 주식(ERNA)의 최신 뉴스
Eterna Therapeutics Completes Public Offering to Bolster Capital - TipRanks
Ernexa Therapeutics Signs Multiple Financing Agreements - TradingView
What hedge fund activity signals for Ernexa Therapeutics Inc. stockJuly 2025 PostEarnings & Target Return Focused Picks - mfd.ru
Ernexa Therapeutics prices $10.5 million public offering at $0.50 per share - Investing.com
Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering - The Manila Times
Ernexa Therapeutics Inc. Announces Pricing of $10.5 Million Public Offering of Common Stock and Warrants - Quiver Quantitative
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Street Watch: Is Ernexa Therapeutics Inc forming bullish engulfing patternsQuarterly Investment Review & Reliable Entry Point Alerts - baoquankhu1.vn
Valuation Update: Why is Ernexa Therapeutics Inc stock going up2025 Volume Leaders & Proven Capital Preservation Methods - baoquankhu1.vn
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Ernexa Therapeutics Advances toward First-in-Human Trial for Ovarian Cancer Following Successful Pre-IND Meeting with FDA - Quiver Quantitative
Ernexa Therapeutics Participates in Virtual Investor “What - GlobeNewswire
Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA - Yahoo Finance
Japanese trade program selects Ernexa Therapeutics among elite biotech group - Investing.com Canada
Ernexa Therapeutics Selected for Japan Entry Acceleration Program to Advance Innovative Cell Therapies - Quiver Quantitative
Ernexa Therapeutics Selected as One of Only Ten Global - GlobeNewswire
New Highs: Can Ernexa Therapeutics Inc be recession proofEarnings Overview Report & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Can Ernexa Therapeutics Inc. be recession proofJuly 2025 News Drivers & Low Risk Entry Point Guides - baoquankhu1.vn
Breakout Zone: Is RICK showing insider buyingRisk Management & Growth Focused Investment Plans - baoquankhu1.vn
Update Report: Is Ernexa Therapeutics Inc forming bullish engulfing patternsEarnings Recap Summary & Long Hold Capital Preservation Plans - baoquankhu1.vn
Can Ernexa Therapeutics Inc continue delivering strong returnsPortfolio Gains Report & Reliable Intraday Trade Plans - baoquankhu1.vn
Volume Report: What is TTGTs revenue forecastTrade Risk Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Ernexa Therapeutics (NASDAQ:ERNA) vs. Inotiv (NASDAQ:NOTV) Critical Review - Defense World
Market Recap: Can Ernexa Therapeutics Inc continue delivering strong returnsJuly 2025 PostEarnings & Low Risk High Reward Ideas - baoquankhu1.vn
Aug PostEarnings: Will Ernexa Therapeutics Inc. stock recover faster than peersMarket Performance Report & Weekly Top Performers Watchlists - Bộ Nội Vụ
Bull Run: How institutional buying supports Ernexa Therapeutics Inc stockJuly 2025 Trends & Low Drawdown Momentum Trade Ideas - Bộ Nội Vụ
Is Ernexa Therapeutics Inc. stock trading at a premium valuationJuly 2025 Pullbacks & Technical Pattern Alert System - Улправда
How Ernexa Therapeutics Inc. stock reacts to inflationary pressures2025 Price Momentum & Daily Price Action Insights - Улправда
How Ernexa Therapeutics Inc. stock compares to industry benchmarksCPI Data & Low Risk High Win Rate Picks - ulpravda.ru
Ernexa’s stem cell therapy could soon enter ovarian cancer trials - Rare Cancer News
Why Penguin Solutions Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket - Benzinga
Ernexa Therapeutics announces successful pre-Ind FDA meeting - marketscreener.com
Ernexa receives FDA alignment for ovarian cancer cell therapy By Investing.com - Investing.com Canada
Ernexa Therapeutics Advances Ovarian Cancer Treatment Toward First-in-Human Trial After FDA Meeting - Quiver Quantitative
Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-In-Human Trial in Ovarian Cancer - marketscreener.com
Will Ernexa Therapeutics Inc. stock pay special dividends2026 world cup usa national team group stage key players possession football group prediction preview - Улправда
Ernexa Stock Drops On 1-For-15 Reverse Stock Split To Regain Nasdaq Compliance: Retail Sentiment Improves But Stays Bearish - MSN
Published on: 2026-01-02 17:34:55 - Bộ Nội Vụ
How Low Can Ernexa Therapeutics Stock Really Go? - Trefis
Is Ernexa Therapeutics Inc. stock attractive for growth ETFsEarnings Growth Report & Technical Confirmation Trade Alerts - DonanımHaber
How Ernexa Therapeutics Inc. stock performs in rate cut cyclesQuarterly Earnings Report & Expert Curated Trade Setups - DonanımHaber
Ernexa Therapeutics (NASDAQ:ERNA) Stock Price Down 5.1% – Here’s What Happened - Defense World
Ernexa Therapeutics Earnings Notes - Trefis
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Ernexa Therapeutics stock falls after ASH meeting presentation By Investing.com - Investing.com Australia
Ernexa Therapeutics stock falls after ASH meeting presentation - Investing.com
Ernexa reports promising preclinical data for cancer cell therapy By Investing.com - Investing.com Australia
Ernexa Therapeutics Presents New Preclinical Data on ERNA-101 at ASH Annual Meeting Highlighting Innovative Cell Therapy Potential to Combat Cancer - Quiver Quantitative
Ernexa reports promising preclinical data for cancer cell therapy - Investing.com
Ernexa Therapeutics Presents New Preclinical Data at - GlobeNewswire
Ernexa Therapeutics (ERNA) Stock Analysis Report | Financials & Insights - Benzinga
With Ernexa Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis
Can Ernexa Therapeutics Stock Recover If Markets Fall? - Trefis
Ernexa Therapeutics Inc. (ERNA) 5.2% in After-hours: Strong Presentation Initiative - Stocks Telegraph
Ernexa Therapeutics announces oral presentation at the 67th American Society of Hematology - marketscreener.com
Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting - GlobeNewswire
Can Ernexa Therapeutics Inc. stock hit analyst price targetsWeekly Stock Recap & AI Powered Trade Plan Recommendations - Newser
How Ernexa Therapeutics Inc. stock compares to market leadersTrade Analysis Summary & Verified Stock Trade Ideas - Newser
Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG - markets.businessinsider.com
1.24%
0.19%
자본화:
|
볼륨(24시간):